NasdaqGS - Nasdaq Real Time Price USD

Kailera Therapeutics, Inc. (KLRA)

16.41 +0.20 (+1.23%)
As of 9:31:43 AM EDT. Market Open.
Chart Range Bar
Loading chart for KLRA
  • Previous Close 16.21
  • Open 16.26
  • Bid 11.70 x 200
  • Ask 16.93 x 100
  • Day's Range 16.21 - 16.54
  • 52 Week Range 16.19 - 28.23
  • Volume 49,684
  • Avg. Volume 740,722
  • Market Cap (intraday) 2.127B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.25
  • Earnings Date (est.) Oct 29, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 42.40

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

www.kailera.com

145

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

KLRA
36.88%
S&P 500 (^GSPC)
12.36%

1-Year Return

KLRA
36.88%
S&P 500 (^GSPC)
19.06%

3-Year Return

KLRA
36.88%
S&P 500 (^GSPC)
70.63%

5-Year Return

KLRA
36.88%
S&P 500 (^GSPC)
70.07%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -78.86M
Profit Margin 0.00%

Q1

FY26

-60M
-40M
-20M
0
0.0%
 

Analyst Insights

View More

Analyst Price Targets

30.00
42.40 Average
16.41 Current
57.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 5/12/2026
Analyst Leerink Partners
Rating Action Initiated
Rating Outperform
Price Action Announces
Price Target 36
 

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    2.40B

  • Enterprise Value

    1.50B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.15

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -292.2M

  • Diluted EPS (ttm)

    -2.25

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    916.74M

  • Total Debt/Equity (mrq)

    0.91%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

16.41 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

People Also Watch